Axogen, Inc Reports First Quarter 2024 Financial Results
Axogen, Inc. (AXGN)
Last axogen, inc. earnings: 2/24 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.axogeninc.com
Company Research
Source: GlobeNewswire
ALACHUA, Fla. and TAMPA, Fla., May 02, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the first quarter ended March 31, 2024. First Quarter Financial Results First quarter revenue was $41.4 million, a 12.9% increase compared to the first quarter of 2023.In the first quarter of 2024, our gross margin increased to 78.8%, up from 77.7%, as reclassified* in the same quarter of the previous year.Net loss for the quarter was $6.6 million, or $0.15 per share, compared to net loss of $7.1 million, or $0.17 per share in the first quarter of 2023.Adjusted net loss for the quarter was $2.7 million, or $0.06 per share, compared to adjusted net loss of $4.1 million, or $0.10 per share in the first quarter of 2023.Adjusted EBITDA was $1.0 million for the quarter, compared to an adjusted EBITDA loss of $3.8 million in the fir
Show less
Read more
Impact Snapshot
Event Time:
AXGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AXGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AXGN alerts
High impacting Axogen, Inc. news events
Weekly update
A roundup of the hottest topics
AXGN
News
- Axogen Inc. Initiates Rolling Submission of Biologics License Application to U.S. Food and Drug Administration (FDA) for Avance Nerve Graft® [Yahoo! Finance]Yahoo! Finance
- Axogen Inc. Initiates Rolling Submission of Biologics License Application to U.S. Food and Drug Administration (FDA) for Avance Nerve Graft®GlobeNewswire
- Axogen, Inc to Participate at Leerink Partners Healthcare Crossroads Conference [Yahoo! Finance]Yahoo! Finance
- Axogen, Inc to Participate at Leerink Partners Healthcare Crossroads ConferenceGlobeNewswire
- AxoGen, Inc. (NASDAQ: AXGN) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.MarketBeat
AXGN
Earnings
- 5/2/24 - Beat
AXGN
Sec Filings
- 5/2/24 - Form 10-Q
- 5/2/24 - Form 8-K
- 4/30/24 - Form EFFECT
- AXGN's page on the SEC website